View in EDS

Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.

Saved in:
Bibliographic Details
Title: Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.
Authors: Reutens AT; Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Lekamlage DH; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Victoria, Australia., Salim A; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia., Shaw JE; Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia., Esler MD; Human Neurotransmitter Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia., Cooper ME; Department of Diabetes, Monash University, Central Clinical School, Melbourne, Victoria, Australia., Kaye DM; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Monash Alfred Baker Centre for Cardiovascular Research, Monash University, Melbourne, Victoria, Australia. Electronic address: david.kaye@baker.edu.au.
Source: JACC. Advances [JACC Adv] 2025 Dec; Vol. 4 (12 Pt 2), pp. 102304. Date of Electronic Publication: 2025 Nov 08.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918419284106676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2772-963X (Electronic) Linking ISSN: 2772963X NLM ISO Abbreviation: JACC Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41205543
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Reutens+AT%22">Reutens AT</searchLink>; Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Lekamlage+DH%22">Lekamlage DH</searchLink>; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Salim+A%22">Salim A</searchLink>; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Shaw+JE%22">Shaw JE</searchLink>; Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Esler+MD%22">Esler MD</searchLink>; Human Neurotransmitter Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Cooper+ME%22">Cooper ME</searchLink>; Department of Diabetes, Monash University, Central Clinical School, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Kaye+DM%22">Kaye DM</searchLink>; Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Monash Alfred Baker Centre for Cardiovascular Research, Monash University, Melbourne, Victoria, Australia. Electronic address: david.kaye@baker.edu.au.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918419284106676%22">JACC. Advances</searchLink> [JACC Adv] 2025 Dec; Vol. 4 (12 Pt 2), pp. 102304. <i>Date of Electronic Publication: </i>2025 Nov 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918419284106676 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2772-963X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222772963X%22">2772963X </searchLink><i>NLM ISO Abbreviation: </i>JACC Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41205543
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jacadv.2025.102304
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102304
    Titles:
      – TitleFull: Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Reutens AT
      – PersonEntity:
          Name:
            NameFull: Lekamlage DH
      – PersonEntity:
          Name:
            NameFull: Salim A
      – PersonEntity:
          Name:
            NameFull: Shaw JE
      – PersonEntity:
          Name:
            NameFull: Esler MD
      – PersonEntity:
          Name:
            NameFull: Cooper ME
      – PersonEntity:
          Name:
            NameFull: Kaye DM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2772-963X
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 12 Pt 2
          Titles:
            – TitleFull: JACC. Advances
              Type: main
ResultId 1